Johnson & Johnson Has $196,000 Stock Position in BiomX Inc. (NYSEMKT:PHGE)

Johnson & Johnson cut its stake in shares of BiomX Inc. (NYSEMKT:PHGE) by 90.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 192,321 shares of the company’s stock after selling 1,730,880 shares during the period. BiomX accounts for 0.0% of Johnson & Johnson’s holdings, making the stock its 18th largest position. Johnson & Johnson’s holdings in BiomX were worth $196,000 as of its most recent filing with the Securities & Exchange Commission.

Separately, Ikarian Capital LLC acquired a new stake in shares of BiomX in the first quarter valued at approximately $4,868,000. 40.57% of the stock is currently owned by institutional investors and hedge funds.

BiomX Stock Down 0.9 %

Shares of NYSEMKT:PHGE traded down $0.00 during midday trading on Wednesday, hitting $0.55. The stock had a trading volume of 53,627 shares, compared to its average volume of 68,601. The stock has a fifty day moving average price of $0.85 and a 200-day moving average price of $1.99. The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $9.98 million, a P/E ratio of -0.17 and a beta of 1.31.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of BiomX in a report on Friday, August 16th.

BiomX Profile

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.